World's Best Scientists 2026 revealed!
Andrew Grigg

Andrew Grigg

D-Index & Metrics

Medicine

D-Index
76
Citations
20685
World Ranking
18798
National Ranking
630

Andrew Grigg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew Grigg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 473 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew Grigg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Grigg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew Grigg is affiliated with the Austin Hospital in Australia and has a research focus centered within the field of Medicine, with significant contributions to subfields such as Hematology, Genetics, Pathology and Forensic Medicine, Oncology, and Immunology.

Their work prominently addresses topics related to blood cancers and related disorders. Notable main topics covered in their research include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders

Andrew Grigg has published numerous papers in several frequent venues, displaying a focus on hematology and oncology journals. The key publication venues for their work include:

  • Leukemia & Lymphoma / Leukemia and Lymphoma (11 publications)
  • Blood (11 publications)
  • British Journal of Haematology (5 publications)
  • Haematologica (5 publications)
  • Internal Medicine Journal (5 publications)

Their recent papers cover a range of topics in hematology and lymphoma treatment. Selected recent publications include:

  • "Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia," 2020, British Journal of Haematology
  • "Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study," 2021, Haematologica
  • "Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study," 2023, HemaSphere
  • "Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience," 2020, British Journal of Haematology
  • "Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy," 2020, American Journal of Hematology

Collaboration plays a significant role in Andrew Grigg's research. Frequent coauthors in their body of work include:

  • Eliza A. Hawkes (11 joint publications)
  • Kate Manos (9 joint publications)
  • David M. Ross (8 joint publications)
  • Anthony P. Schwarer (7 joint publications)
  • Nada Hamad (6 joint publications)

Best Publications

  • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson

  • High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Andrew Grigg

  • Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

    Harrison Cn;Campbell Pj;Buck G;Wheatley K

  • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

    Mary E D Flowers;Jane F. Apperley;Koen Van Besien;Ahmet Elmaagacli

  • An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study

    G. M. Mead;M. R. Sydes;J. Walewski;A. Grigg

  • Optimizing Dose and Scheduling of Filgrastim (Granulocyte Colony- Stimulating Factor) for Mobilization and Collection of Peripheral Blood Progenitor Cells in Normal Volunteers

    Andrew P. Grigg;Andrew W. Roberts;Heike Raunow;Sue Houghton

  • All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

    Harry J. Iland;Harry J. Iland;Ken Bradstock;Ken Bradstock;Shane G. Supple;Alberto Catalano

  • Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

    David Ross;Susan Branford;John F Seymour;Anthony Schwarer

  • Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

    Stephen M Ansell;Monique C Minnema;Peter Johnson;John M Timmerman

  • Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

    Susan Branford;Zbigniew Rudzki;Ian Parkinson;Andrew Grigg

  • Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

    Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

  • Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation

    Charles G. Mullighan;Sue Heatley;Kathleen Doherty;Ferenc Szabo

  • FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS

    R.K. Woodruff;A.P. Grigg;F.C. Firkin;I.L. Smith

  • Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

    Susan Branford;David T. Yeung;Wendy T. Parker;Wendy T. Parker;Nicola D. Roberts

  • Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

    S Branford;Z Rudzki;A Harper;A Grigg

  • Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

    Timothy P. Hughes;Susan Branford;Deborah L. White;John Reynolds

  • In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

    Deborah White;Verity Saunders;A. Bruce Lyons;Susan Branford

  • Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

    A Grigg;C G Begley;C A Juttner;J Szer

Frequent Co-Authors

Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Kenneth F. Bradstock
Kenneth F. Bradstock Westmead Hospital
Andrew Spencer
Andrew Spencer Monash University
Constantine S. Tam
Constantine S. Tam University of Melbourne
John V. Reynolds
John V. Reynolds Trinity College Dublin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For prospective medical students in the USA, there are many alternative online degrees and career pathways to explore. Online programs offer convenience and flexibility, which is especially vital for working professionals or those with family commitments.

Nursing is one popular route. Candidates aiming for advanced practice roles can consider a 1 year dnp program online, which can accelerate the transition to leadership positions in clinical settings. Those looking to enter nursing quickly might opt for fast track lpn programs online, allowing for rapid entry into the healthcare workforce.

Mental health is another expanding field. The fastest psych np program offers a streamlined way to become a Psychiatric Nurse Practitioner—preparing graduates for critical roles in mental health care.

Not all career pathways require direct patient care. Those interested in the business and administrative side of healthcare may choose from the cheapest mha programs online, gaining essential management skills with lower tuition costs.

Exploring these diverse online programs can help you find the right fit for your lifestyle, budget, and career goals within the healthcare industry.

Best Scientists Citing Andrew Grigg

Trending Scientists

Recently Published Articles